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Abstract
Corticotropin releasing factor receptor 1 (CRF1) is the key receptor that mediates stress-related body responses. However to
date there are no CRF1 antagonists that have shown clinical efficacy in stress-related diseases. We investigated the inhibitory
effects of a new generation, topology 2 selective CRF1 antagonists, NGD 98-2 and NGD 9002 on exogenous and
endogenous CRF-induced stimulation of colonic function and visceral hypersensitivity to colorectal distension (CRD) in
conscious rats. CRF1 antagonists or vehicle were administered orogastrically (og) or subcutaneously (sc) before either
intracerebroventricular (icv) or intraperitoneal (ip) injection of CRF (10 mg/kg), exposure to water avoidance stress (WAS,
60 min) or repeated CRD (60 mmHg twice, 10 min on/off at a 30 min interval). Fecal pellet output (FPO), diarrhea and
visceromotor responses were monitored. In vehicle (og)-pretreated rats, icv CRF stimulated FPO and induced diarrhea in
.50% of rats. NGD 98-2 or NGD 9002 (3, 10 and 30 mg/kg, og) reduced the CRF-induced FPO response with an inhibitory
IC50 of 15.7 and 4.3 mg/kg respectively. At the highest dose, og NGD 98-2 or NGD 9002 blocked icv CRF-induced FPO by 67–
87% and decreased WAS-induced-FPO by 23–53%. When administered sc, NGD 98-2 or NGD 9002 (30 mg/kg) inhibited icv
and ip CRF-induced-FPO. The antagonists also prevented the development of nociceptive hyper-responsivity to repeated
CRD. These data demonstrate that topology 2 CRF1 antagonists, NGD 98-2 and NGD 9002, administered orally, prevented icv
CRF-induced colonic secretomotor stimulation, reduced acute WAS-induced defecation and blocked the induction of
visceral sensitization to repeated CRD.
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Introduction
Corticotropin releasing factor (CRF), a 41-amino acid peptide
originally isolated from ovine brain extract, is the principal
mediator of the hypothalamic-pituitary-adrenal (HPA) stress–
response [1,2] CRF exerts its biological functions by activating two
classes of B subfamily G-protein coupled receptors, CRF1 and
CRF2 receptors [3]. Activation of brain CRF1 signaling by CRF
peptides plays a pivotal role in the behavioral, endocrine, immune,
autonomic, and visceral responses to stress [2,4–6]. One of the
bodily systems susceptible to stress and stress-related peptides is the
gastrointestinal tract [7]. Specifically, acute stressors and CRF
injected into the brain or the periphery induces a rapid onset
stimulation of colonic motor function in rodents, a response that is
largely mediated by activating CRF1 receptors in both the brain
and the colon and reproducing symptoms of irritable bowel
syndrome (IBS) with diarrhea (IBS-D) [8,9].
Preclinical and early clinical studies support the possibilities that
pharmacological interventions targeting CRF1 signaling may have
potential therapeutic benefits in alleviating stress sensitive disor-
ders [10,11]. For instance, the peptide CRF receptor antagonist,
a–CRF9–41, injected into the circulation alleviates symptoms in a
subclass of IBS patients [12]. As peptide compounds are less
desirable in drug development, non-peptide small molecule CRF
receptor antagonists are being developed to treat anxiety,
depression, alcoholism, drug relapse and stress-related gastroin-
testinal diseases [10,13–15]. Progress in the therapeutic use of non-
peptide CRF1 antagonists, however, has been slow and largely
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disappointing due in part to the lack of consistency in their
efficacy. For instance, chronic administration of a selective CRF1
antagonist, R121919/NBI 30775, showed anxiolytic and antide-
pressant effects in the first open-label clinical study in patients with
major depressive episodes [16]. NBI-34041 showed efficacy
against the Trier social stress-induced endocrine response in
placebo-controlled phase I and II clinical trials performed in
healthy subjects [11]. There is also preliminary evidence that
R317573 exerts anxiolytic effects in healthy subjects subjected to
7.5% carbon monoxide inhalation, an experimental model of
anxiety [17]. Similarly, in a recent randomized, double-blind,
placebo-controlled study, the selective CRF1 antagonist GSK-
GW876008 decreased brain regional activity associated with the
emotional-arousal network during expectation of abdominal pain
in IBS patients [14]. On the other hand, the CRF1 antagonists,
CP-316,311, showed no effect against depression in a 6-week
randomized, placebo-controlled trial [18] and pexacerfont did not
demonstrate efficacy compared to placebo for the treatment of
generalized anxiety disorders in a multi-center clinical trial [19].
With regard to IBS, a double blind placebo-controlled clinical
report showed the lack of effect of the CRF1 selective antagonist
BMS-562086 in ameliorating gastrointestinal symptoms in IBS-D
patients [15].
Enthusiasm for the first generation of selective non-peptide
CRF1 antagonists, including CP-154,526 [20] and SSR125543A
[21] was dampened by their pharmacokinetic properties. Overall
the CRF1 antagonists, with demonstrated high selectivity and
potency in in vitro biological tests and preclinical assays, were
highly lipophilic and hence less attractive for therapeutic use due
to the potential risk of elevated tissue accumulation and prolonged
half life [22,23]. Furthermore, the improvements in decreasing
lipophilicity are not necessarily translated to higher oral bioavail-
ability. Thus, to date there are very few CRF1 receptor antagonists
with high oral bioavailability and desirable pharmacokinetic
profile.
Recently, we have developed and described a new generation of
topology 2 selective CRF1 antagonists with pyrazine cores, namely
NGD 98-2 (5-(2-Methoxy-4-trifluoromethoxyphenyl)-[N-(1-ethyl)propyl]-
3-methoxy-6-methylpyrazine-2-amine tosylate) and NGD 9002 (5-(6-
isopropyl-2-methylaminopyridin-3-yl)-[N-(1-ethyl)propyl]-3-methoxy-6-
methylpyrazine-2-amine hydrochloride). These compounds displayed
K(i) values below 10 nM with acceptable properties and minimal
toxicity [24,25]. In vivo, oral pretreatment with NGD 98-2
prevented intracerebroventricular (icv) CRF-induced increased
locomotor activity and acute restraint-stress-induced elevation of
plasma ACTH levels in rats [24].
In this study, we examined the antagonist action of NGD 98-2
and NGD 9002 on CRF-induced IBS-D-like symptoms, namely
altered colonic motor function and visceral nociceptive hyper-
responsiveness to colorectal distention (CRD) in conscious rats.
We first delineated the doses at which orogastric (og) and
subcutaneous (sc) administration of these compounds will antag-
onize CRF injected icv or intraperitoneally (ip)-induced stimula-
tion of colonic propulsive motor function and diarrhea [26,27].
We then used the maximal effective oral dose of NGD 98-2 and
NGD 9002 to assess whether this will counteract defecation
induced by water avoidance stress (WAS) and the development of
visceral hypersensitivity induced by repeated tonic CRD in rats
known to involve activation of CRF1 signaling [27–29].
Materials and Methods
1. Animals
Adult male Sprague-Dawley rats (Harlan, San Diego, Califor-
nia, USA) weighing 280–320 g were housed in group cages with
free access to Purina rat chow and tap water. Animals were
quarantined under controlled conditions of illumination (12 h
light/dark cycle; lights on 06:00 h), temperature, and humidity for
at least one week. Experiments started between 9 am and 10 am
in non-fasted rats unless otherwise stated. Experimental protocols
were approved by the Animal Care Committee of the Veteran
Affairs Greater Los Angeles Healthcare System (#06-069-02) and
the UCLA Animal Research Committee UCLA (ARC #2002-
042).
2. Substances
NGD 98-2 (5-(2-methoxy-4-trifluoromethoxyphenyl)-[N-(1-
ethyl)propyl]-3-methoxy-6-methylpyrazine-2-amine tosylate)
(Fig. 1A) and NGD 9002 (5-(6-isopropyl-2-methylaminopyridin-
3-yl)-[N-(1-ethyl)propyl]-3-methoxy-6-methylpyrazine-2-amine
hydrochloride) (Fig. 1B) were synthesized at Neurogen Corpora-
tion (Branford, CT, USA) [24]. For oral preparation, a day before
the experiment, compounds were sonicated and suspended in
0.5% methylcellulose in distilled water with 0.1% triacetin (Sigma-
Aldrich Co., St. Louis, MO) and placed on a magnetic stir plate
overnight. For sc injection, NGD 98-2 and NGD 9002 were
dissolved in dimethyl sulfonic acid (DMSO, Sigma-Aldrich):Tw-
een-80:saline (1:1:8 ratio). Rat/human CRF and astressin (Clayton
Foundation Laboratories for Peptide Biology, Salk Institute, La
Jolla, CA, USA) were kept at –80o C in powder form and diluted
in saline just before administration. The selective non-peptide
CRF1 antagonist, CP-154,526 (Pfizer, Groton, CT, USA) [30] was
diluted in a DMSO:Tween-80-:saline (1:1:8 ratio) solution as
described before [31]. The pH of compound solutions at different
concentrations was measured and respective vehicles were
adjusted to be at the same pH.
3. Substance Administration
The volume of administration varied with the route of delivery:
og, 5 or 10 ml/kg; sc, 1.5 ml/kg; ip, 1.0 ml/kg; icv, 10 ml/rat.
The og gavage was performed using a stainless steel tubing
(Cadence, Inc. Staunton, VA) in lightly hand-restrained rats and
the sc injection was made into the loose skin of the back over the
shoulders.
The icv injections were performed as in our previous studies
[32]. Conscious lightly restrained rats with chronic icv cannula
were injected through a 28 ga cannula (Plastics One Inc.,
Roanoke, VA, USA), 1 mm longer than the guide cannula. The
Figure 1. Chemical structures of A=NGD 98-2:5-(2-Methoxy-4-
trifluoromethoxyphenyl)-[N-(1-ethyl)propyl]-3-methoxy-6-
methylpyrazine-2-amine tosylate. B =NGD 9002:5-(6-isopropyl-2-
methylaminopyridin-3-yl)-[N-(1-ethyl)propyl]-3-methoxy-6-methylpyra-
zine-2-amine hydrochloride.
doi:10.1371/journal.pone.0073749.g001
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injection cannula was connected to a 50 ml Hamilton syringe by a
PE-50 tubing (Intramedic Polyethylene Tubing, Clay Adams,
Sparks, MD, USA) filled with distilled water. A small air bubble
(1 ml) was drawn at the distal end of the PE-50 tubing to separate
the injected solution from the water and for visual monitoring of
the icv injection which was performed slowly over a 60-sec period.
At the end of experiments, animals were euthanized with sodium
pentobarbital overdose followed with bilateral thoracotomy. In icv
cannulated rats, the correct location of the cannula into the lateral
ventricles was assessed by injecting icv 0.1% toluidine blue (10 ml)
and the visualization of dye on the walls of lateral ventricles.
The regimens of compound administration were as follow: the
sc injection of NGD 98-2 was performed 60 min before icv or ip
CRF (Fig. 2A and B) and og administration, 180 min before icv
CRF (Fig. 3) or WAS. Oro-gastric or sc NGD 9002 was given
60 min before icv (Fig. 2 A) or ip CRF (Fig. 4) or WAS (Fig. 5). For
CRD-induced visceral nociceptive responsivity, both NGD 98-2
and NGD 9002 were given og 40 min prior to the 1st CRD (Fig 6
and 7). These dosing regimens were based on our previous report
showing that NGD 98-2 given orally 180 min before icv CRF
prevents the CRF-induced increased locomotor activity or
restraint stress-induced elevation of plasma ACTH levels [24] as
well as pilot studies to assess optimal inhibitory effect on icv CRF-
induced defecation.
4. Surgeries
4.1. Intracerebroventricular cannulation. ICV cannula-
tion was performed as previously reported [32]. Rats were
anesthetized with an ip injection of a mixture of ketamine
(75 mg/kg; Fort Dodge Laboratories, Fort Dodge, IA, USA) and
xylazine (5 mg/kg; Mobay Corporation, Shawnee, KS, USA). A
chronic guide cannula (22 ga, Plastic One Products) was
implanted into the right lateral brain ventricle according to
coordinates from Paxinos and Watson [33] (mm from bregma:
antero–posterior, 20.8; lateral, 21.5; dorsoventral, 23.5). The
guide cannula was maintained in place by dental cement anchored
by four stainless steel jewelry screws fixed to the skull. The cannula
was capped with a dummy cannula for protection. Following icv
cannulation, rats were housed singly and allowed to recover for at
least 7-10 days during which they were trained to the experimen-
tal conditions of icv injection by handling them for 5 min per day
for at least 3 consecutive days.
4.2. Abdominal muscle electrodes implantation. The
implantation of electrodes was performed in rats anesthetized with
an ip injection of a mixture of ketamine (75 mg/kg) and xylazine
(5 mg/kg) as detailed in previous studies [34]. Under aseptic
conditions, a 2–3 cm incision was made near the lower abdomen
along the mid-line. The abdominal muscle layers and the
peritoneum were opened and a group of 3 teflon coated silver
electrodes were fixed in triangular pattern (5 mm apart) on the left
side of the abdominal muscle 1–2 cm lateral to the mid line. The
other end of the electrodes was fitted in a small plastic casing,
which served as a jack to connect the electrodes to the recording
device. The connecting side of the jack was then exteriorized on
the right side of the flank (2–3 cm lateral to the mid-line) through a
small (3 mm diameter) opening across the abdominal wall and the
skin. The base of the jack was secured in place by suturing it onto
the peritoneal side of the abdominal muscle. Rats were allowed to
recover from surgery for 10–15 days.
5. Procedures
5.1. Water avoidance stress. The WAS was performed as
described before [35] by placing the rat on a small cubic pedestal
(8 cm height, 6 cm wide) positioned in the center of a plastic cage
filled with room temperature water up to 7 cm height of the
pedestal. To avoid contact with the water, the rat remains on the
pedestal platform for the experimental period.
5.2. Measurements of abdominal contractions to
colorectal distention. Rats chronically fitted with electrodes
on abdominal muscles were trained to the experimental conditions
by placing them in Bollman cages for 2–3 h/day for at least 3
consecutive days before the study. On the day of the experiment,
rats were briefly anaesthetized with isoflurane (3% in O2), and a
6 cm long plastic balloon tied around an Intramedic PE-100
tubing (Becton Dickinson, Franklin Lakes, NJ, USA) was inserted
intra-anally with the distal end positioned 1 cm proximal to the
anus. The CRD in awake rats results in contractions of the
abdominal and hind limb musculature and this visceromotor
response (VMR) is validated as a quantitative measure of visceral
hypersensitivity [36]. The protocol of CRD was similar to our
previous studies showing the induction of visceral hypersensitivity
[29,37]. CRD entailed inflating the CRD balloon with a barostat
(Distender II, J&J Inc., Toronto, ON, Canada) at 60 mmHg twice
for 10 min with a 30 min rest interval. The VMR to CRD was
Figure 2. Subcutaneous injection of CRF1 antagonists, NGD
9002 or NGD 98-2 prevents central (icv) or systemic (ip) CRF-
induced stimulation of propulsive colonic motor function in
conscious rats. A: Rats with chronic icv cannula were pretreated sc
with vehicle, NGD 98-2 or NGD 9002 and 60 min later were injected icv
with saline or CRF and FPO monitored for 60 min. B: Rats were
pretreated sc with either vehicle or NGD 98-2 (3, 10, 30 mg/kg) and
60 min later, they were injected ip with CRF or saline. As a positive
control, a group of rats was injected sc with a known CRF1 antagonist,
CP154,526, 60 min prior to ip CRF and FPO monitored for 60 min. Each
bar represents the mean and SEM of 8 rats/group. *p,0.05 compared
with sc vehicle+icv saline group (A) or vs sc vehicle+ip saline group (B);
#p,0.05 compared with sc vehicle+icv CRF (A), or vs sc vehicle+ip CRF
B), ANOVA, Student-Newman-Keuls.
doi:10.1371/journal.pone.0073749.g002
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recorded as electromyography (EMG) signals and acquired using a
Micro1401 A/D interface (Cambridge Electronic Design, Ltd,
Cambridge, UK) connected to a Pentium IV class computer
running Spike 2 data acquisition software. EMG signals were
amplified, filtered (x10000, 300–5000 Hz), digitized, and rectified
as detailed previously [38]. The basal area under the curve (AUC)
of abdominal contractions recorded from EMG was calculated as
the area under the rectified EMG signal trace for the 10 min
period immediately preceding the first 10 min CRD. The AUC
values of the EMG during the first and second distensions were
computed and basal AUC subtracted to obtain the net AUC in
response to CRD as described [37]. AUC of contractions in
response to each 10 min distention was compared to each other.
From these values, the percent change in AUC [DAUC (%)] was
calculated by taking the difference between the 1st and 2nd
distention AUC responses and dividing by the 1st AUC and
multiplying by 100.
5.3. Colonic motor function measurements. Defecation
was monitored as described previously [31] by counting the
number of fecal pellets excreted every 15 min for up to 2 h. The
incidence of diarrhea was assessed for the 2-h period post CRF
injection as percent of rats that developed one loose-watery stool
or more from the total number of treated rats.
6. Experimental Protocols
All the experiments started between 9–10 am and were
conducted in non-fasted conscious rats trained to the experimental
conditions. Unless otherwise stated, antagonists were administered
following a regimen of 60 min pretreatment period.
6.1. Effect of NGD 98-2 or NGD 9002 injected
subcutaneously on intracerebroventricular or
intraperitoneal CRF-induced stimulation of colonic
secretomotor function. Groups of rats (n = 8/group) were
injected sc with either vehicle (DMSO:Tween 80:saline in 1:1:8
ratio), NGD 98-2 or NGD 9002 (30 mg/kg) before icv CRF
(10 mg/kg) or saline. Fecal pellet output (FPO) was then monitored
for 60 min post icv injection.
In a separate experiment, rats (n = 8/group) were injected sc
with either vehicle, NGD 98-2 (3, 10 or 30 mg/kg) or CP 154,526
(20 mg/kg) followed with ip saline or CRF (10 mg/kg) and fecal
pellet and diarrhea responses were monitored for 60 min post ip
injection. We previously reported the efficacy of CP 154,526
(20 mg/kg) against ip CRF (10 mg/kg) -induced stimulation of
defecation in rats [39] and this CRF1 antagonist at such a dose was
used as a positive control.
6.2. Dose-related effect of NGD 98-2 or NGD 9002
administered orogastrically on CRF or water avoidance
stress-induced colonic motor response. For intracerebro-
ventricular CRF, saline or CRF (10 mg/kg) was injected icv in
chronically cannulated rats, 180 min or 60 min after og admin-
istration of vehicle (0.5% methylcellulose in distilled water with
0.1% triacetin), NGD 98-2 (3, 10 or 30 mg/kg) or NGD 9002 (3,
10 or 30 mg/kg) (n = 8/group). The FPO and diarrhea responses
were monitored for 60 or 120 min post icv injection.
For intraperitoneal CRF, in a separate set of experiments, NGD
9002 (3, 10 or 30 mg/kg) or its vehicle was administered
orogastrically before ip injection of CRF (10 mg/kg) or saline
(n = 8/group). The defecation response was monitored for 60–
120 min. The peptide CRF antagonist astressin injected ip
(30 mg/kg) immediately before ip CRF (10 mg/kg) was used as
positive control. Astressin under these conditions is known to block
ip CRF-mediated colonic response [31].
For water avoidance stress, rats were pretreated orogastrically
with either vehicle (0.5% methylcellulose in distilled water with
0.1% triacetin) or NGD 98-2 (3, 10 or 30 mg/kg) or NGD 9002
(3, 10 or 30 mg/kg) and 180 min later (for NGD 98-2) or 60 min
later (for NGD 9002), rats (n = 8/group) were either left
undisturbed in their home cage (no stress) or exposed to WAS
for 60 min.
6.3. Effect of orally-administered NGD 98-2 or NGD 9002
on repeated colorectal distention-induced visceral
nociceptive sensitization. After rectocolonic positioning of
the balloon and recovery from the short anesthesia, rats were
administered og with NGD 9002 (10 or 30 mg/kg, n= 8 or 17/
group) or NGD 98-2 (30 mg/kg, n = 10) or their vehicle (0.5%
methylcellulose/0.1% triacetin, n= 22) and placed in Bollman
cages. After a 30-min stabilization period and 10-min baseline
recording, all groups were submitted to isobaric CRD (60 mm Hg
for 10 min twice, with a 30 min rest interval) using a barostat. The
abdominal contraction responses to the 1st and 2nd distention were
compared within and between groups.
7. Statistical Analysis
Values are expressed as mean and standard error of the mean or
mean % difference. The FPO response to different treatments or
doses was compared using a one-way analysis of variance
(ANOVA). Comparison between groups on diarrhea incidence
(%) was made using Fisher’s exact test. Two way ANOVA was
used, to compare the two factor effects of NGD 9002 and NGD
98-2 (0, 3, 10, 30 mg/kg) on CRF or WAS-induced FPO
responses. Similarly, where appropriate, IC50 of NGD compounds
was calculated using Graphpad Prism Software (GraphPad
Software, Inc. La Jolla, CA). The AUC of abdominal contraction
response to the 1st vs 2nd distension within a group were compared
using before and after paired t-test or one-way repeated measures
ANOVA and percent differences using t-test or ANOVA. For pair
wise multiple comparisons, Student-Newman-Keuls Method or
Fisher LSD test was used. P,0.05 was considered as a significant
difference.
Results
1. NGD 98-2 or NGD 9002 Injected Subcutaneously
Inhibits icv and ip CRF-induced Stimulation of Propulsive
Colonic Motor Function in Rats
In chronic icv cannulated rats, CRF (10 mg/kg, icv) injected
60 min after vehicle increased FPO compared to icv saline
(number/60 min: 4.860.8 vs 0.060.0; p,0.05; n = 8/group).
Pretreatment (30 mg/kg sc, 260 min) with NGD 98-2 or NGD
9002 inhibited icv CRF-induced FPO by 71% for each compound
(1.460.6 and 1.460.6 pellet/60 min respectively, p,0.05, n= 8/
group) (Fig. 2A).
Similarly, in vehicle pretreated (sc,260 min) rats, ip injection of
CRF (10 mg/kg), significantly stimulated FPO compared with
saline (number/60 min 6.660.9 vs 0.560.3; p,0.05; n= 8/
group). Pretreatment (30 mg/kg sc, 260 min) with NGD 98-2
inhibited significantly the colonic response to ip CRF by 59%
(2.561.2 pellet/1h; p,0.05, n = 8/group) (Fig. 2B) while at lower
doses (3 and 10 mg/kg, sc), NGD 98-2 had no significant effect
(5.361.6 and 6.161.9 pellet/1h, respectively; p.0.05, n= 8/
group, Fig. 2B). Rats pretreated (sc, 260 min) with the highest
dose of NGD 98-2 (30 mg/kg) had a similar reduction of ip CRF-
induced stimulation of FPO as that of the known selective CRF1
antagonist, CP154,526 (20 mg/kg, sc 260 min) (Fig. 2B). NGD
98-2 at 30 mg/kg alone had no effect on FPO (Fig. 2B).
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2. NGD 98-2 or NGD 9002 given Orally Decreases Dose-
dependently icv-CRF-Induced Stimulation of Propulsive
Colonic Motor Function
In vehicle-pretreated (og, 2180 min) rats with a chronic icv
cannula, CRF (10 mg/kg, icv) significantly stimulated FPO
compared with the og vehicle+icv saline group during the
60 min period post icv injection (6.861.8 vs 0.560.3 pellets/
60 min; n= 8/group, p,0.05, Fig. 3A). In addition, 50% of the
icv CRF-injected rats developed diarrhea (P= 0.07). Pretreatment
(og, 2180 min) with NGD 98-2 (3, 10, and 30 mg/kg, n = 8 for
each dose), dose-dependently inhibited the FPO responses to icv
CRF vs vehicle (pellets/60 min: 5.161.5, 3.461.2, and 0.960.7
respectively vs 6.861.8, p,0.05 at the highest dose) with an IC50
of 15.7 mg/kg (Fig. 3A). There was also a non-significant trend
towards reduction of the 50% incidence of diarrhea in the og
vehicle+icv CRF group to 25%, 37.5%, and 0% in response to og
pretreatment with NGD 98-2 at 3, 10 and 30 mg/kg, respectively
(Fig. 3B). Likewise, pretreatment (-60 min) with NGD 9002 (3, 10,
and 30 mg/kg, og, n = 8 for each dose) reduced the icv CRF-
stimulated FPO (5.961.5 vs iccv saline 0.360.3 number/60 min,
p,0.05) to 3.960.7, 3.061.4 and 1.960.9 number/60 min
respectively (p,0.05 at the highest dose, Fig. 3C) with an IC50
of 4.3 mg/kg. Orogastric NGD 9002 also reduced dose-depen-
dently the icv CRF-induced 75% incidence of diarrhea reaching
significance at the 30 mg/kg dose (12.5%, p,0.05; Fig. 3D). NGD
98-2 (30 mg/kg, og), used as a positive control in this particular
experiment, completely prevented the incidence of icv CRF-
induced diarrhea (0%, p,0.05; Fig. 3D). In the absence of CRF,
NGD 9002 alone (30 mg/kg, og) had no effect on FPO or
diarrhea (Fig. 3C–D). A two-way ANOVA to assess drug (NGD
98-2 and NGD 9002) and dose (0, 3, 10 and 30 mg/kg)
interactions showed a significant main effect of drug (p,0.01) as
well as dose (p,0.01) on icv CRF-induced FPO response and no
significant interaction between drug type and dose (P= 0.396).
3. NGD 9002 Administered Orogastrically and Astressin
Intraperioneally Reduce ip-CRF-induced Colonic
Responses
In vehicle-pretreated (-60 min) rats, CRF injected ip (10 mg/kg)
stimulated fecal output (3.661.0 vs 0.860.3 pellets/60 min;
p = 0.05; n= 8/group, Fig. 4A). Compared to vehicle, CRF
injection induced also diarrhea in 50% of rats (0% vs 50%,
p= 0.07, Fig. 4B). Pretreatment (-60 min) with NGD 9002 (3, 10
and 30 mg/kg, og, n= 8 for each dose) induced a trend to reduce
ip-CRF stimulated FPO which did not reach statistical significance
(2.061.0 and 1.160.9 pellet/60 min at 10 and 30 mg/kg,
respectively; 8/group, p =.0.05, Fig. 4A). Similarly, compared
to the vehicle group, 50% of the vehicle+ip CRF or NGD 9002
(3 mg/kg)+ip CRF-treated rats had diarrhea (0% vs 50%,
p= 0.07, n= 8/group, Fig 4B). The diarrhea response was
14.3% and 0% in NGD 9002-treated rats at 10 and 30 mg/kg
respectively (n = 8 for each dose, Fig. 4B). Compared with rats
pretreated with ip saline, astressin (30 mg/kg, ip) abolished both
the FPO (4.061.3 vs 0 pellet/60 min, p,0.05, Fig. 4A) and
diarrhea (75% vs 0%, p,0.05, Fig. 4B) responses to ip CRF.
4. NGD 98-2 or NGD 9002 given Orogastrically Decreases
Acute Water Avoidance Stress-induced Colonic Motor
Response in Rats
The exposure to WAS for 60 min stimulated FPO compared
with non-stressed rats maintained in their home cage (8.860.6 vs
1.460.6 pellet/60 min, p,0.05, n = 8/group, Fig. 5A). Pretreat-
ment with NGD 98-2 (3, 10 and 30 mg/kg, n = 8 for each dose)
administered og 180 min before stress attenuated significantly
WAS-induced colonic response (8.860.6 pellet/60 min) to
5.560.8, 5.560.9, and 6.860.4/60 min respectively (Fig. 5A).
Similarly, NGD 9002 administered orally (3, 10, and 30 mg/kg,
260 min, n= 8 for each dose) reduced WAS-stimulated FPO
compared with vehicle+WAS group (2.660.6, 1.960.8, and
1.860.6 vs 3.860.5 number/60 min respectively (Fig. 5B). Post-
hoc comparisons showed a significant reduction of fecal pellets at
30 mg/kg NGD 9002 and at 10 and 30 mg/kg NGD 98-2. In
control rats (non-stressed), NGD 9002 (30 mg/kg, po) alone had
no effect on FPO (Fig. 5B).
5. Orogastric Administration of NGD 98-2 or NGD 9002
Decreases Repeated Tonic Colorectal Distention-induced
Visceral Nociceptive Hyper-responsivity
Two tonic colorectal distensions (60 mmHg for 10 min with a
30 min interval) increased the VMR monitored by increased
EMG activity (Fig. 6A–B). A representative trace of the abdominal
contraction response to tonic distensions in vehicle or NGD 98-2
(30 mg/kg, og) pretreated rats (-40 min before 1st CRD) is shown
in Fig. 6A and 6B respectively. The mean percent difference
between the 1st and 2nd responses in the vehicle-pretreated rats
was significantly higher than the mean percent difference in NGD
98-2-pretreated rats (60.4633.4% vs 238.2619.2%, p,0.05,
n = 8-10/group, Fig. 6C). In addition, while 5 out of 8 vehicle-
pretreated rats (62.5%) had at least a 10% higher response to the
2nd distention when compared to the 1st, only 1 out of 10 rats
(10%) pretreated with NGD 98-2 (30 mg/kg) had a 10% or higher
response to the 2nd CRD when compared to the 1st.
In a separate study where the effect of NGD 9002 was evaluated
in a larger number of rats (n = 8–22/group), repeated CRD
resulted in a significantly increased 2nd CRD response (p,0.05,
Fig. 7A & 7C). As in the NGD 98-2 experiment, the mean percent
difference between the 1st and 2nd responses in the vehicle-
pretreated rats (n = 22) was significantly higher than the mean
percent difference of NGD 9002 at 30 mg/kg group (n= 17)
(Fig. 7C). In addition, while 9 out of 22 vehicle pre-treated rats
(41%) had at least a 10% higher response to the 2nd CRD, when
compared to the 1st, none of the 8 rats pretreated with NGD 9002
at 10 mg/kg and only 2 out of 17 of the NGD 9002 at 30 mg/kg
had a 10% or higher response to the 2nd CRD compared with the
1st (Fig. 7A-C).
Discussion
NGD 98-2 and NGD 9002 were identified as pre-clinical
development candidates from drug discovery efforts spanning
several series of topology 2 CRF1 antagonists. These compounds
display high affinity (less than 10 nM) to both human and rat
CRF1 receptors (Ki = 1.0 and 9.8 nM for NGD 98-2 and Ki= 2.3
and 4.3 nM for NGD 9002 respectively) and demonstrate oral
efficacy [24,25]. The present study shows that NGD 98-2 and
NGD 9002, administered orogastrically, dampen centrally or
peripherally injected CRF- or acute WAS-induced colonic motor
stimulation (defecation) and repeated tonic CRD-induced visceral
sensitization in rats. These data indicate the effectiveness of orally
administered NGD 98-2 and NGD 9002 against exogenous CRF
and endogenous CRF released by acute WAS [27,35]-induced
IBS-D-like symptoms in rats.
CRF injected icv at a dose of 10 mg/kg produced a significant
and reproducible increase in FPO and incidence of diarrhea in
50% of rats. This is consistent with previous reports showing that
icv CRF-induced enhanced colonic secretory and motor function
[27,28,40]. Orogastric administration of the selective CRF1
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antagonists, NGD 98-2 [24] or NGD 9002 [25] dose-dependently
reduced the icv CRF-induced FPO. NGD 98-2 also dose-
dependently prevented the incidence of diarrhea induced by icv
CRF while NGD 9002 showed a non-significant trend. Previous
studies in rats showed that icv injection of the CRF1 antagonist,
NBI-27914 blocked icv CRF-induced defecation [28,41]. The
present data provide the first evidence that an orally administered
CRF1 antagonist abolished icv CRF induced stimulation of both
colonic propulsive motor function and diarrhea. This supports the
efficacy of orally administered new generation CRF1 antagonists
against centrally mediated CRF stimulatory effects on colonic
secretory-motor function. We have recently reported that NGD
98-2 crosses the blood brain barrier upon orogastric administra-
tion to block icv CRF mediated increased locomotor activity in
rats [24]. The present data extend these findings to the
gastrointestinal tract. In addition, the fact that og administration
of NGD 9002 has an in vivo IC50 value of 4.3 mg/kg compared to
15.7 mg/kg for NGD 98-2 in blocking icv CRF-induced
defecation, while both NGDs have similar Ki to rat CRF1
[24,25] suggests that NGD 9002 and NGD 98-2 may have ability
to cross the blood brain barrier to block exogenous CRF action in
the brain. This is of significance because most of the selective
CRF1 antagonists used in prior studies to address the role of CRF1
in central CRF-induced colonic stimulation had to be adminis-
tered through systemic or central injections due to their poor oral
bioavailability [28,31,41]. The few CRF1 antagonists that show
oral bioavailability were tested with either peripheral injection of
CRF [34] or mainly in the context of icv CRF-induced behavioral
outcomes such as increased locomotion, addiction, depression and
anxiety [10,22,24]. The single double-blind placebo controlled
clinical trial that evaluated the effect of an orally-administered
CRF1 antagonist, BMS-562086 on gastrointestinal outcomes
showed no improvement in colonic transit in IBS-D predominant
patients [15]. The current study is the first to demonstrate the
efficacy of orally administered selective non-peptide CRF1
antagonists to alleviate central CRF-induced colonic stimulation
in rats. Of note, most of the CRF1 antagonists tested in prior
studies had limitations for clinical use in part due to their high
lipophilicity [22,42].
Next we tested whether systemic or orogastric administration of
NGD 9002 and NGD 98-2 would influence the colonic response
to peripherally injected CRF. Intraperitoneal injection of CRF is
well-established to act through distinct mechanisms than those
initiated in the brain by central injection of CRF [43]. CRF
injected ip or locally induces a direct activation of colonic
cholinergic myenteric neurons, stimulates colonic 5-HT release
and activates mast cells [44,45]. NGD 98-2 injected sc at 30 mg/
kg unlike lower doses (10 or 3 mg/kg) reduced defecation induced
by ip CRF. Additionally NGD 9002 given orally at 30 mg/kg
reduced icv CRF-induced defecation and showed a non-significant
trend to reduce the incidence of diarrhea induced by ip CRF.
Under the same conditions, the peptide CRF1/CRF2 antagonist
astressin [46] injected ip at 30 mg/kg completely prevented both
the defecation and diarrhea as previously reported [31]. Consistent
with these findings, the CRF1 antagonist NBI 35965 injected sc or
og (10–20 mg/kg) reduced ip or intravenous CRF induced
stimulation of distal colonic transit in rats [34]. The present data
are also in line with reported preventive action of other CRF1
antagonists such as CP-154,526 given sc against ip CRF or the
selective CRF1 agonist, cortagine,-induced stimulation of colonic
motor function [31,47].
The effects of central and peripheral CRF on the colon have
long been suggested to mimic those produced by acute stressors
[48]. In particular, acute exposure to WAS produced a reliable
and significant increase in FPO which we demonstrated previously
to involve activation of CRF1 receptors located in both the brain
Figure 3. Oro-gastric (og) administration of CRF1 antagonist, NGD 98-2 or NGD 9002 blunts icv CRF-induced defecation and
diarrhea in rats with chronic icv cannula. NGD 98-2 (3, 10 and 30 mg/kg) or saline was given og 180 min before icv CRF or saline and fecal
output (A) and diarrhea (B) were monitored for 1 h post icv injection. NGD 9002 (3, 10, 30 mg/kg) or saline was given 60 min before icv CRF and FPO
(C) and diarrhea (D) monitored for 1 h post icv injection. Each bar in A and C represents the mean and SEM while each bar in B and D represents
mean % of 8 rats/group. *p,0.05 compared with og vehicle+icv saline group (A-D); #p,0.05 compared with og vehicle+icv CRF (A-D), ANOVA,
Student-Newman-Keuls; t-test; Fisher Exact test.
doi:10.1371/journal.pone.0073749.g003
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and the colon [6]. In the present study, orogastric administration
of NGD 9002 and NGD 98-2, while having no effect on defecation
in a non-stressed rat, effectively reduced the enhanced colonic
motor response caused by WAS. To date, with the exception of
one study that tested the efficacy of an orogastrically-administered
CRF1 antagonist, NBI 35965 on defecation induced by WAS [34],
the overwhelming majority of studies on acute stress-induced
colonic motor stimulation have used sc injections of the non-
peptide selective CRF1 antagonist CP-154,524 [31,49]. The
present study adds, to the orally-active selective CRF1 antagonists,
two novel compounds for use in preclinical and potential clinical
studies on gut motor response to stress.
Lastly, while non-selective and selective CRF1 antagonists have
been well documented to prevent stress- or icv or ip CRF-induced
visceral sensitization in rodents [34,47,50–53], the effects of orally-
active CRF1 antagonists against nociceptive hyper-responsivity to
tonic noxious colonic stimulation have not been studied. Repeated
tonic CRD-induced visceral hypersensitivity has been established
in rats [29,37,54], mice [55], and humans [56,57]. In rats, we
previously reported that such a hypersensitization is not associated
with colonic lesion and is prevented by the ip injection of a
selective CRF2 receptor agonist, urocortin-2 [37], a sc injection of
a selective CRF1 antagonist antalarmin [29] or by oral adminis-
tration of pregabalin, a ligand to the a2d subunit of the voltage-
gated calcium channel [58]. In the present study, repeated tonic
CRD resulted in an enhanced VMR to the 2nd distention
compared to the 1st, indicating the development of acute
hypersensitivity to a noxious visceral stimuli. This response is
prevented by oral-administration of NGD 98-2 and NGD 9002,
indicative of a role of CRF1 in the response. The demonstration of
the involvement of CRF1 in repeated mechanical CRD-induced
nociceptive hyper-responsivity is in line with previous studies using
sc antalarmin [29].
The exact site(s) and mechanism(s) of action of the orally-active
NGD compounds cannot be determined from the present study.
Tonic CRD is shown to activate ERK phosphorylation in the
lumbosacral spinal segments in rats and the response is blunted by
CRF2 activation [37]. Spinal ERK phosphorylation modulates
neuronal excitability and plays an important role in hyperalgesia
after noxious somatic stimuli and inflammation [59] suggesting a
possible sensitization occurring during repeated CRD as well. On
the other hand, activation of peripheral CRF1 receptors by the
CRF1 selective peptide agonist, cortagine, causes visceral hyper-
algesia in rats [47] suggesting a possible peripheral action of orally-
administered NGD compounds to prevent repeated tonic CRD-
induced sensitization. Taken together, given that both central and
peripheral sensitizations are reported to occur during visceral
hyperalgesia [60] and the fact that the orally-administered NGD
98-2 crosses the blood brain barrier with high brain exposure
leading to CRF1 receptor occupancy assessed by autoradiography
[24], it is likely that the compounds block CRF1-mediated central
and peripheral visceral hyper responsiveness.
Figure 4. Oro-gastric (og) administration of NGD 9002 exerted
a non-significant trend towards reduction of ip CRF-induced
FPO and diarrhea in rats. Vehicle or NGD 9002 (3, 10 and 30 mg/kg)
was given og 60 min before ip CRF-induced FPO (A) and diarrhea (B)
which were monitored for the 60 min post ip injection. As a positive
control, group of rats were pretreated with ip astressin (30 mg/kg), a
non selective CRF1 and CRF2 receptor antagonist, just prior to ip CRF.
Each bar in A represents the mean and SEM of FPO while in B they
represent the mean % of 8 rats/group. *p,0.05 vs saline+vehicle or
saline+NGD 9002 (30 mg/kg); #p,0.05 compared with the correspond-
ing ip astressin+ip CRF. ANOVA, Student-Newman-Keuls; t-test; Fisher
Exact test.
doi:10.1371/journal.pone.0073749.g004
Figure 5. Oro-gastric (og) administration of NGD CRF1
antagonist, NGD 98-2 or NGD 9002 reduces acute water
avoidance stress (WAS)-induced stimulation of colonic propul-
sive motor function in rats. Vehicle or NGD 98-2 (A) or NGD 9002 (B)
at 3, 10 and 30 mg/kg was administered po and 180 min later (for NGD
98-2 group) or 60 min later (for NGD 9002 group), rats were exposed to
WAS for 60 min. FPO was monitored during the 60 min stress session.
Each bar represents the mean and SEM of 8 rats/group. *p,0.05
compared with vehicle og+no stress; #p,0.05 compared with vehicle
og+WAS, ANOVA, Student-Newman-Keuls.
doi:10.1371/journal.pone.0073749.g005
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In summary, significant progress has been made in the design
and development of non- peptide CRF1 receptor antagonists
[22,61]. However, high lipophilic characteristics and potential
toxicity have hampered their translational applications [22,42,61].
Thus, of the numerous non-peptide small molecule CRF1
antagonists developed, to date very few have moved forward to
clinical trials [13,61]. NGD 98-2 and NGD 9002 are topology 2
CRF1 antagonists with high affinity to CRF1, high oral
bioavailablity and low lypophilicity. Orally-administered NGD
98-2 and NGD 9002 effectively prevented icv CRF-induced
activation of defecation in rats. The present data show also that the
selective CRF1 antagonists blunt WAS-induced colonic motor
activation and prevented repeated CRD-induced visceral hyper-
sensitivity. The data strengthen the concept that activation of
CRF1 signaling pathway plays a role in mediating acute stress-
related stimulation of colonic motor function as well as visceral
sensitization to CRD in healthy rats. Although, several preclinical
studies have shown, early on, the role of CRF1 receptors in stress-
related colonic stimulation and suggested a therapeutic potential of
CRF1 antagonists against stress-related diarrhea and visceral
hypersensitivity [7,40,50], the report that a CRF1 antagonist lacks
efficacy to influence intestinal transit and diarrhea in IBS patients
[15], raises concern on the potential use of CRF1 antagonists to
alleviate symptoms in IBS patients. Several reasons including the
testing of CRF1 antagonists in preclinical studies mainly in an
acute stress-context, while in clinical studies the state of acute or
chronic stress of patients is not well determined; the presence of
over 11 splice variants of CRF1 receptors in humans [62]; the
existence of differences in binding kinetics, association and
dissociation rate and efficacy of CRF1 antagonists used [61,63]
may account for the discrepancy. There is also a lack of
information, in previous clinical studies, on whether the antagonist
regimens used is optimum to block both central and peripheral
Figure 6. Oro-gastric (og) pretreatment with NGD 98-2 blunts
repeated tonic colorectal distention (CRD)-induced visceral
sensitization response in conscious rats. Representative trace of
abdominal muscle electromyogram (EMG) of rats pretreated with
vehicle (A) or NGD 9002 (B). Percent difference in the area under the
curve of contraction (AUC) between the 1st and the 2nd dissentions is
shown in C. Rats were chronically implanted with abdominal electrodes
and ,10 days later were pretreated og with vehicle or NGD 98-2
(30 mg/kg). After 30 min of habituation and 10 min basal recording,
rats were submitted to the first CRD (10 minutes at 60 mm Hg) followed
by a 30 min rest and a 2nd 10 min distention at 60 mmHg. Values are
mean and SEM of percent differences between the first and second
responses to CRDs of 9–10 rats/group. *p,0.05 versus vehicle, t-test or
ANOVA, Student-Newman-Keuls.
doi:10.1371/journal.pone.0073749.g006
Figure 7. Oro-gastric (og) pretreatment with NGD 9002 blunts
repeated tonic colorectal distention (CRD)-induced visceral
sensitization response in conscious rats. Rats were chronically
implanted with abdominal electrodes and ,10 days later were
pretreated og with vehicle or NGD 9002 (0, 10 or 30 mg/kg). After
30 min of habituation and 10 min basal recording, rats were submitted
to the 1st CRD (10 minutes at 60 mm Hg) followed by a 30 min rest and
a 2nd 10 min distention at 60 mmHg. Representative trace of abdominal
muscle electromyogram (EMG) of rats pretreated with vehicle (A) or
NGD 9002 (B). Percent difference in the area under the curve of
contraction (AUC) between the 1st and the 2nd dissentions in saline and
NGD 9002 treated rats is shown in C. Values are mean and SEM of
percent differences between the first and second responses to CRDs of
8–22 rats/group. *p,0.05 versus vehicle, t-test or ANOVA, Student-
Newman-Keuls.
doi:10.1371/journal.pone.0073749.g007
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CRF1 receptors. In this context, the development of new CRF1
antagonists such as NGD 98-2 and NGD 9002 that have better
oral bioavailability opens new venues to understand the potential
role and mechanisms of CRF1 receptors in stress-sensitive
functional bowel disorders such as IBS.
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